← Amphastar Pharmaceuticals, Inc.

Annual Trend FY 2016 FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025
Cash flows from operating activities:
Adjustments to reconcile net income to net cash provided by operating activities:
Net Income (Loss) Attributable to Parent $10.5m $4.5m ($5.7m) $48.9m $1.4m $62.1m $91.4m $137.5m $159.5m $98.1m
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest — — ($6.7m) $46.5m $1.1m $63.3m $91.4m $137.5m $159.5m $98.1m
Net Income (Loss) Attributable to Noncontrolling Interest — — ($922k) ($2.4m) ($306k) $1.2m — — — —
Depreciation, Depletion and Amortization $12.0m $12.6m $14.5m $7.1m $9.0m $10.2m $12.6m $25.7m $28.2m $31.6m
Depreciation $12.0m $12.6m $14.5m $17.1m $20.5m $22.2m $23.8m $25.2m $28.2m $31.6m
Amortization of Debt Issuance Costs — — — — — $219k $466k $11.4m $6.0m $3.4m
Amortization of Intangible Assets $2.5m $2.9m $2.0m $1.0m $1.0m $1.3m $1.4m $12.8m $24.7m $25.0m
Capitalized Computer Software, Amortization — — — — — — — — — $0
Deferred Income Tax Expense (Benefit) ($4.0m) $2.7m ($4.4m) $7.5m $917k $3.7m ($15.9m) ($13.9m) ($17.1m) $28.7m
Share-based Payment Arrangement, Noncash Expense $15.1m $17.1m $16.7m $17.3m $20.5m $18.7m $17.9m $20.2m $24.4m $27.3m
Share-based Payment Arrangement, Expense $15.1m $17.1m $16.7m $17.3m $20.5m $18.7m $17.9m $20.2m $24.4m $27.3m
Gain (Loss) on Disposition of Assets — — — ($1.0m) ($240k) ($348k) ($141k) ($475k) ($9k) ($39k)
Gain (Loss) on Disposition of Intangible Assets — $2.6m — — — — — — — —
Gain (Loss) on Disposition of Property Plant Equipment ($1.2m) $2.3m ($1.4m) $17.1m $20.5m $22.2m $23.8m $25.2m $28.2m $31.6m
Income (Loss) from Equity Method Investments — — — — — ($208k) ($1.2m) ($2.0m) ($573k) —
Income Tax Expense (Benefit) $4.4m ($2.9m) ($3.3m) $13.7m $3.5m $20.6m $23.5m $31.8m $29.7m $25.5m
Interest Expense Nonoperating — — — — — — — — $30.3m $25.5m
Other Nonoperating Income (Expense) $8k $2.9m ($1.5m) $59.4m ($6.6m) $14.5m $9.1m ($3.9m) $4.1m $23k
Changes in operating assets and liabilities:
Additional Financial Items
Increase (Decrease) in Accounts Receivable ($6.4m) $8.1m $16.3m ($6.7m) $20.2m $14.9m $10.1m $26.1m $21.7m $6.4m
Increase (Decrease) in Inventories $9.7m ($18.6m) $6.0m $41.1m ($15.3m) ($1.3m) $11.7m $1.7m $48.8m $21.1m
Proceeds from Stock Options Exercised $20.3m $19.1m $11.8m $7.8m $24.4m $16.8m $19.2m $14.2m $12.2m $6.4m
Accretion Expense $72k — — — — — — — — —
Deconsolidation, Gain (Loss), Amount — — — — — $13.6m — — — —
General and Administrative Expense $41.8m $44.5m $49.9m $50.3m $50.4m $51.4m $45.1m $51.5m $56.7m $85.9m
Goodwill $4.0m $4.5m $4.0m $3.6m $3.9m $3.3m $3.1m $3.2m $3.0m $3.4m
Inventory Write-down — $8.5m $12.9m $9.4m $13.9m $24.6m $17.2m $18.8m $14.0m $6.0m
Investment Income, Interest $270k $425k $456k $997k $642k $601k $1.3m $5.5m $10.6m $8.7m
Nonoperating Income (Expense) ($746k) $2.5m ($1.3m) $60.3m ($6.3m) $14.3m $8.5m ($25.6m) ($15.7m) ($16.8m)
Operating Expenses $88.5m $91.7m $115.6m $132.0m $132.4m $129.9m $141.4m $154.1m $168.4m $215.7m
Pension Cost (Reversal of Cost) $200k $200k $300k $200k $200k $200k — — $0 $0
Net Cash Provided by (Used in) Operating Activities $38.6m $39.2m $38.2m $41.8m $57.3m $98.0m $89.2m $183.5m $213.4m $156.1m
Cash flows from investing activities:
Payments to Acquire Property, Plant, and Equipment $21.4m $35.1m $46.8m $41.6m $33.9m $27.5m $24.0m $38.2m $41.0m $34.9m
Net Cash Provided by (Used in) Investing Activities ($39.5m) ($38.8m) ($42.2m) ($50.5m) ($36.4m) ($28.7m) ($32.8m) ($649.1m) ($124.9m) ($70.3m)
Cash flows from financing activities:
Proceeds from Issuance of Long-term Debt $10.2m $19.0m $8.4m $3.6m $6.3m $70.0m — $845.0m — —
Repayments of Long-term Debt $14.7m $9.7m $5.7m $6.4m $8.4m $36.7m $1.8m $318.7m $8.3m $223k
Payments for Repurchase of Common Stock $9.9m $30.7m $25.0m $22.3m $24.4m $28.9m $39.9m $58.1m $85.5m $75.6m
Net Cash Provided by (Used in) Financing Activities $7.1m ($7.7m) $25.0m ($3.8m) ($2.2m) ($37.0m) ($26.4m) $454.1m ($81.0m) ($67.4m)
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $81k $504k ($274k) ($104k) $352k ($223k) ($220k) ($282k) ($190k) $210k
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect — ($4.9m) $20.7m ($12.7m) $19.0m $32.1m $29.7m ($11.8m) $7.3m $18.6m
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents — ($4.9m) $88.2m $75.5m $94.5m $126.6m $156.3m $144.5m $151.8m $170.4m
Restricted Cash and Investments, Current — $4.2m $4.2m — — — — — — —
Supplemental disclosure of cash flow information:
Interest Paid, Excluding Capitalized Interest, Operating Activities $1.7m $1.9m $2.4m $2.4m $2.2m $2.1m $3.0m $17.6m $26.8m $23.2m
Income Taxes Paid, Net $3.4m $4.9m $339k $5.7m $3.4m $8.1m $44.4m $49.0m $40.1m $22.7m

Data sourced from SEC EDGAR 10-K filings via EdgarTools. Amounts are shown in USD as reported in each fiscal year filing.